Skip to content

Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2026-525256-29-00
Enrollment
36
Registered
2026-03-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comparative bioavailability study under fasting conditions

Interventions

None listed

Sponsors

ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 5, 2026